Piramal Pharma Peer Comparison

NSE: PPLPHARMA | BSE: 543635

₹218.68

₹3.73 (1.74%)

As on 28-Aug-2026IST

Market cap

₹29,103 Cr

Revenue (TTM)

₹9,205 Cr

P/E Ratio

P/B Ratio

3.6

Div. Yield

0 %

Edit

	Piramal Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Granules India
Market cap (₹ Cr)	29,103	32,104	29,892	26,871	20,739
Revenue (₹ Cr)	9,205	3,564	1,936	1,462	5,632
Net Profit (₹ Cr)	-371.81	414.00	288.22	387.35	662.35
Net Margin (%)	-3.93	11.23	14.79	26.01	11.75
RoE (%)	-3.85	8.38	29.77	25.18	14.34
Price to Earnings	--	78.49	103.71	69.57	31.31
Price-To-Book	3.64	6.38	22.27	15.55	4.23

Income Statement (₹ Cr)

	Piramal Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Granules India
Operating Revenue	8,869.08	3,373.00	1,753.96	1,006.88	5,365.64
Total Income	9,111.51	3,510.00	1,762.66	1,023.80	5,385.97
Total Expenditure	7,976.59	2,747.00	1,354.69	774.80	4,180.50
EBITDA	892.49	626.00	399.26	232.07	1,185.14
Depreciation	831.24	227.00	45.26	26.62	296.14
EBIT	61.25	399.00	354.00	205.45	889.00
Interest	340.80	213.00	42.17	6.22	114.35
Other Income	242.43	137.00	8.70	16.93	20.33
Exceptional Items	-196.14	-85.00	--	--	-10.00
Profit before Tax	-176.06	238.00	320.53	216.16	784.98
Provision for Tax	149.88	39.00	73.80	55.75	189.96
Profit after Tax	-325.94	199.00	246.74	160.42	595.02

	Piramal Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Granules India
Shareholder's Funds	8,162.62	4,940.00	1,288.82	1,309.63	5,085.00
Minority Interest	--	341.00	0.00	10.45	--
Non-Current Liabilities	4,529.41	1,235.00	189.02	26.93	479.08
Current Liabilities	4,874.74	1,622.00	835.87	202.25	2,092.03
Total Liabilities	17,723.32	8,578.00	2,326.71	1,549.26	7,682.91

	Piramal Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Granules India
Non-Current Assets	10,258.66	5,441.00	631.90	757.63	3,888.46
Current Assets	7,308.11	2,606.00	1,681.81	791.64	3,767.65
Total Assets	17,723.32	8,578.00	2,326.71	1,549.26	7,682.91
Total Debt*	5,495.48	2,125.00	259.37	8.18	1,338.13
Net Current Assets	2,433.37	984.00	845.94	589.39	1,675.62
Contingent Liabilities	95.72	768.26	19.09	15.38	0.93

	Piramal Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Granules India
Cash From Operating Activities	1,652.60	390.00	205.05	118.34	793.25
Cash Flow from Investing Activities	-826.03	-241.00	-409.72	-223.94	-773.21
Cash from Financing Activities	-38.98	-54.00	283.07	261.12	379.29
Net Cash Inflow / Outflow	787.59	95.00	78.39	155.52	399.33

	Piramal Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Granules India
ROCE (%)	1.24	6.79	29.22	20.14	15.74
ROE (%)	-4.04	4.29	27.84	16.19	14.13
ROA (%)	-1.98	2.53	13.11	12.13	8.60
EBIT Margin (%)	12.80	22.62	23.26	24.73	22.47
Net Margin (%)	-3.58	5.67	14.00	15.67	11.05
Cash Profit Margin (%)	4.80	10.98	7.71	18.58	8.89

	Piramal Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Granules India
Revenue Growth (%)	-3.08	11.99	36.57	40.34	19.73
EBIT Growth (%)	-28.15	67.69	52.29	83.12	25.81
Net Profit Growth (%)	-457.66	449.12	83.64	229.35	18.64
EPS Growth (%)	-456.91	553.20	71.44	67.16	16.13
Book Value Growth (%)	0.33	13.47	144.31	94.96	27.49

	Piramal Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Granules India
Price / Earnings	0.00	89.54	51.69	62.97	25.87
Price / Book Value	2.24	3.87	10.14	15.26	3.26
Dividend Yield (%)	0.00	0.00	0.19	0.06	0.28
EV/EBITDA	19.72	27.45	31.05	79.31	13.09
Market Cap (₹ Cr)	18,108.89	19,071.62	12,753.19	19,988.69	15,391.88

	Piramal Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Granules India
Debt to Equity	0.68	0.43	0.21	0.01	0.28
Short term debt to equity ratio	0.09	0.09	0.05	0.01	0.20
Current Ratio	1.50	1.61	2.01	3.91	1.80
Quick Ratio	0.87	1.06	1.14	3.02	1.00
Interest Coverage	0.48	2.12	8.60	35.76	7.86

	Piramal Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Granules India
Debtors to sales (%)	24.33	17.43	29.00	28.85	16.95
Asset Turnover	0.64	0.49	2.01	0.76	1.45
Receivable days	78.20	58.75	40.13	90.06	33.72
Inventory Days	93.30	75.82	60.29	61.02	54.92
Payable days	226.14	186.21	232.47	96.06	136.11
Cash Conversion Cycle	-54.64	-51.64	-132.04	55.02	-47.47

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.